Acrivon Therapeutics, Inc. (ACRV)
After hours:
| Previous close | 7.39 |
| Open | 7.44 |
| Bid | 7.29 x 100 |
| Ask | 7.39 x 200 |
| Day's range | 7.23 - 7.54 |
| 52-week range | 3.19 - 14.03 |
| Volume | |
| Avg. volume | 779,463 |
| Market cap | 226.636M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.89 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 22.38 |
ZacksIs Acrivon Therapeutics, Inc. (ACRV) Outperforming Other Medical Stocks This Year?
Here is how Acrivon Therapeutics, Inc. (ACRV) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year.
GlobeNewswireAcrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced the company’s president and chief ex
ZacksHere's Why You Should Buy Acrivon Therapeutics (ACRV) Stock
Here, we discuss some reasons why buying Acrivon Therapeutics (ACRV) stock now may turn out to be a prudent move.
